RS Dalal et al. Clin Gastroenterol Hepatol 2024; 22: 666-668. Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A ...

Tu1826 IMPACT OF GLP-1 RECEPTOR AGONIST ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS: INSIGHTS FROM A LARGE-SCALE ...

Mo1848 UPADACITINIB IS EFFECTIVE AND SAFE FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE: 1-YEAR PROSPECTIVE REAL-WORLD EXPERIENCE

Sa1835 LOW SERUM URIC ACID LEVES ARE ASSOCIATED WITH LOW BONE MINERAL DENSITY IN MALE PATIENTS WITH ULCERATIVE COLITIS

Tu1765 MUCOSAL IGG-LIKE NAIVE B-CELL EXPANSION AND MATURATION CONTRIBUTE TO ULCERATIVE COLITIS PATHOGENESIS

Tu1865 ASSESSING PATIENT-PERCEIVED BURDEN OF DISEASE IN ULCERATIVE COLITIS: A NOVEL SCORING APPROACH IN A REAL-WORLD AUSTRALASIAN COHORT

Tu1890 CLINICAL EFFICACY OF GRANULOCYTE AND MONOCYTE APHERESIS (GMA) IN ULCERATIVE COLITIS. THE EXPERIENCE OF FOUR TERTIARY CENTERS.

Tu1889 REAL-WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD IN ULCERATIVE COLITIS: A MULTICENTER STUDY

Su1786 CORTICOSTEROID-FREE REMISSION THROUGH 2 YEARS OF UPADACITINIB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

30 EARLY INTESTINAL ULTRASOUND RESPONSE TO BIOLOGIC AND SMALL MOLECULE THERAPY PREDICTS ENDOSCOPIC OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS